Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03480334 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy

Study acronym: AERN
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study completion date: Dec 2024 to May 4, 2025v10
  2. Primary completion date changed from estimate of Oct 2023 to May 4, 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 29 to confirmed 26
    • Site details revised
    v9
  3. Primary completion date: May 2023 to Oct 2023v8
  4. Primary completion date: May 2022 to May 2023
    • Study completion date: Dec 2023 to Dec 2024
    v7
  5. Primary completion date: May 2021 to May 2022
    • Study completion date: Aug 2022 to Dec 2023
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Start date changed from estimate of Nov 2019 to Dec 5, 2019v5
  2. Start date: Sep 2019 to Nov 2019v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Mar 2020 to May 2021
    • Start date: Dec 2018 to Sep 2019
    • Study sites: 0 to 1
    v3
  4. Start date: Jul 2018 to Dec 2018v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of the trial is to improve efficacy of nivolumab in patients with relapsed or refractory HL who recently progressed on anti-PD1 therapy. Nivolumab is highly effective and well tolerated in rrHL, nevertheless CR-rates are low and a considerable proportion of patients suffers from progressive disease. Localized RT induces an immunogenic effect which might work synergistically and facilitate augmented systemic (i.e. abscopal) responses in combination with nivolumab.
Trial Details
NCT Number NCT03480334
Lead Sponsor University of Cologne
Conditions
(from sponsor)		 Classical Hodgkin Lymphoma
Enrollment 26 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov